WuXi Biologics, a global contract research, development and manufacturing organisation (CRDMO), has achieved ISO 20400 Sustainable Procurement certification, a globally recognised standard that embeds sustainability principles into procurement practices and promotes transparency, accountability and responsible supply chain management.

The certification underscores WuXi Biologics’ strong performance in sustainability and reflects its ongoing efforts to enhance supply chain resilience while advancing responsible value chain practices across the pharmaceutical industry.

Commenting on the milestone, Dr Chris Chen, chief executive officer of WuXi Biologics and chairman of its ESG Committee, said the company adheres to world-leading management strategies to build a robust and sustainable supply chain. He added that WuXi Biologics remains committed to delivering high-quality solutions to global clients while actively contributing to the advancement of responsible procurement and value chain sustainability.

Sustainability principles are embedded throughout WuXi Biologics’ supplier lifecycle management framework, covering supplier due diligence and onboarding, risk assessment, engagement, performance evaluation and termination. This comprehensive approach ensures that suppliers consistently meet quality, compliance and sustainability requirements, while improving transparency, traceability and operational efficiency and reducing supply chain risks.

Recognising the urgency of addressing climate change, WuXi Biologics has implemented an integrated sustainability strategy supported by measurable Science Based Targets initiative (SBTi) goals and clearly defined roadmaps. In parallel with pursuing its own climate commitments, the company actively collaborates with suppliers through structured sustainable supply chain programmes to drive positive environmental and social outcomes across the value chain.

As a participant of the United Nations Global Compact, WuXi Biologics continues to advocate sustainable business practices and has received multiple global recognitions for its ESG leadership. These include an MSCI AAA rating, an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices, and placement on the CDP “A List” for Climate Change, Water Security and Supplier Engagement. The company has also been rated as negligible risk by Sustainalytics, recognised as an industry and regional ESG leader for five consecutive years, included in the FTSE4Good Index Series and Hang Seng ESG 50 Index, and rated Prime by ISS ESG.

WuXi Biologics provides end-to-end biologics solutions, supporting partners from early discovery through to commercial manufacturing. With a workforce of more than 12,000 employees across China, the United States, Ireland, Germany and Singapore, the company delivers efficient and cost-effective biologics development and manufacturing services. As of 30 June 2025, WuXi Biologics was supporting 864 integrated client projects, including 24 in commercial manufacturing.